23:07 , May 14, 2019 |  BC Extra  |  Company News

Management tracks: DBV, Beam, Aeon Biopharma

DBV Technologies S.A. (Euronext:DBV; NASDAQ:DBVT) said Deputy CEO and Principal Financial Officer David Schilansky will leave the company in August to pursue other opportunities. The allergy company is searching for a new CFO but will...
21:02 , May 14, 2019 |  BC Extra  |  Company News

May 14 Company Quick Takes: F-star rejiggers Merck KGaA deal; plus Roche/Spark, AbbVie/Boehringer, Ipsen

F-star to keep lead bispecific in new deal with Merck KGaA   F-star Biotechnology Ltd. (Cambridge, U.K.) reconfigured its 2017 bispecific antibody deal with Merck KGaA (Xetra:MRK) and will now retain rights to lead candidate...
23:09 , May 10, 2019 |  BioCentury  |  Product Development

Exelixis to fuel pipeline growth with Cabometyx cash flows

On the back of the successful launch of Cabometyx cabozantinib, Exelixis is not only using the increased free cash flow to expand the drug’s label, it also thinks it has the firepower to build out...
16:25 , Apr 19, 2019 |  BioCentury  |  Finance

Earnings on deck

Earnings on deck At least 12 profitable biotechs and pharmas are slated to report earnings this week. (A) During trading hours in Europe; premarket on U.S. exchange; (B) Full-year EPS for fiscal year ended March...
00:16 , Apr 6, 2019 |  BioCentury  |  Finance

Room to rally in 2Q

Strong small and mid-cap performance coupled with robust M&A has brought the sector back from 4Q18 correction territory, and chances are good for the momentum to continue given the ample capital ready to be recycled...
00:06 , Apr 6, 2019 |  BioCentury  |  Finance

Big caps under pressure

Biogen’s fall in the wake of its decision to discontinue late-stage trials of Alzheimer’s therapy aducanumab is yet another reminder that large caps are in dire need of new pipeline products, and could serve as...
22:29 , Mar 12, 2019 |  BC Extra  |  Company News

Management tracks: Inovio, Sangamo, Innate

Inovio CMO Mark Bagarazzi has left the company. Inovio Pharmaceuticals Inc. (NASDAQ:INO) said a newly formed medical council -- VPs of Clinical Development Prakash Bhuyan, Jeffrey Skolnik and Scott White -- will now oversee the...
20:09 , Mar 1, 2019 |  BC Week In Review  |  Company News

Clementia takeout to bolster Ipsen’s orphan pipeline

Ipsen Group (Euronext:IPN; Pink:IPSEY) will broaden its rare disease pipeline by acquiring Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) for $1 billion up front. At $25 per share, the deal price is a 67% premium to Clementia's close...
06:27 , Feb 27, 2019 |  BioCentury  |  Finance

Calypso finds its rhythm

Strong preclinical data and rising interest in IL-15 modulation enabled six-year-old Calypso Biotech B.V. to raise a €20 million ($22.6 million) series A round. The company hopes to start clinical trials next year of lead...
23:11 , Feb 25, 2019 |  BC Extra  |  Company News

Clementia takeout to bolster Ipsen’s orphan pipeline

Ipsen Group (Euronext:IPN; Pink:IPSEY) will broaden its rare disease pipeline by acquiring Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) for $1 billion up front. At $25 per share, the deal price is a 67% premium to Clementia's close...